EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Polymyxin B Intravenous Administration Strategy Guided by Minimum Inhibitory Concentration in Critically Ill Patients With Pulmonary Infection: Insights From PBPK Modeling

Shengnan Zhang iD, Nan Yang iD, Ruwei Yang, Yuanfang Qin, Tingting Wu, Cuifang Wu, Yueliang Xie, Jingjing Liu, Chun Liu, Qi Pei iD

CPT: Pharmacometrics & Systems Pharmacology · 2026-07 · 15 (7)

DOI: 10.1002/psp4.70289 ↗

Kurz gefasst

Fachartikel in der Zeitschrift CPT: Pharmacometrics & Systems Pharmacology, online erschienen am 19.06.2026. Verfasst von Shengnan Zhang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, The Third Xiangya Hospital of Central South University, Changsha, China. Hauptthemen laut MEDLINE: Polymyxin B, Anti-Bacterial Agents, Models, Biological. Die Arbeit nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Intravenous polymyxin B (PMB) is widely used for treating drug‐resistant gram‐negative pneumonia, though its efficacy in pulmonary infections is considered limited. This study aims to identify patients with severe pulmonary infections suitable for treatment with intravenous PMB alone and to recommend individualized optimal dosing regimens. Physiologically based pharmacokinetic (PBPK) models, developed using data from mice, healthy subjects, and critically ill patients, were employed to predict PMB concentrations in epithelial lining fluid (ELF) and plasma. All models were validated against published pharmacokinetic data, and Monte Carlo simulations were used to evaluate various dosing regimens. The therapeutic target was defined as an ELF steady‐state 24 h area under the concentration‐time curve to minimum inhibitory concentration (AUC ss,24h /MIC) ≥ 50. Simulations showed that intravenous PMB maintenance regimens of 100 mg, 1.25 mg/kg, or 1.50 mg/kg q12h enabled 94.4%, 82.2%, and 93.5% of critically ill patients to achieve the ELF pharmacokinetic/pharmacodynamic (PK/PD) target for pathogens with an MIC of 1 mg/L. A plasma AUC ss,24h /MIC threshold of 80.6 was identified as an alternative PK/PD target, with retrospective analysis confirming significantly better outcomes for patients exceeding this threshold ( p = 0.038), warranting prospective validation. Overall, PBPK modeling supports 100 mg or 1.50 mg/kg q12h as candidate initial intravenous regimens for critically ill patients with pulmonary infections. Dosing adjustments based on MIC and plasma AUC ss,24h /MIC value are recommended. Adjunctive nebulization or combination therapy is advised for MICs ≥ 2 mg/L, while 50 mg q12h is sufficient for MICs ≤ 0.5 mg/L. Plasma AUC ss,24h /MIC values exceeding 80.6 may guide individualized dosing when therapeutic drug monitoring is available.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Polymyxin BAnti-Bacterial AgentsModels, BiologicalHumansCritical IllnessAnimalsMonte Carlo MethodFemaleMicrobial Sensitivity TestsMaleAdministration, IntravenousMiceArea Under CurveMiddle AgedAgedAdultDose-Response Relationship, Drug

Stichwörter der Autor:innen

PK/PDintravenous administrationminimum inhibitory concentrationphysiologically based pharmacokinetic modelingpolymyxin Bpulmonary infection

Substanzen

Polymyxin BAnti-Bacterial Agents

Autor:innen und Institutionen

  • Department of Pharmacy, The Third Xiangya Hospital of Central South University, Changsha, China.
  • Department of Intensive Medicine, The Third Xiangya Hospital of Central South University, Changsha, China.
  • Department of Respirology & Critical Care Medicine, The Third Xiangya Hospital of Central South University, Changsha, China.

ORCID-Profile: Shengnan Zhang, Nan Yang, Qi Pei

Zitieren

APA

Zhang, S., Yang, N., Yang, R., Qin, Y., Wu, T., Wu, C., Xie, Y., Liu, J., Liu, C., & Pei, Q. (2026). Polymyxin B Intravenous Administration Strategy Guided by Minimum Inhibitory Concentration in Critically Ill Patients With Pulmonary Infection: Insights From PBPK Modeling. CPT: Pharmacometrics & Systems Pharmacology, 15(7). https://doi.org/10.1002/psp4.70289

Vancouver

Zhang S, Yang N, Yang R, Qin Y, Wu T, Wu C, et al. Polymyxin B Intravenous Administration Strategy Guided by Minimum Inhibitory Concentration in Critically Ill Patients With Pulmonary Infection: Insights From PBPK Modeling. CPT: Pharmacometrics & Systems Pharmacology. 2026;15(7). doi:10.1002/psp4.70289

BibTeX
@article{Zhang2026,
  author = {Zhang, Shengnan and Yang, Nan and Yang, Ruwei and Qin, Yuanfang and Wu, Tingting and Wu, Cuifang and Xie, Yueliang and Liu, Jingjing and Liu, Chun and Pei, Qi},
  title = {Polymyxin B Intravenous Administration Strategy Guided by Minimum Inhibitory Concentration in Critically Ill Patients With Pulmonary Infection: Insights From PBPK Modeling},
  journal = {CPT: Pharmacometrics & Systems Pharmacology},
  year = {2026},
  volume = {15},
  number = {7},
  doi = {10.1002/psp4.70289}
}
Kostenlos starten →